SequelSEC

IMPACT BIOMEDICAL INC. IBO

Pharmaceutical Preparations · CIK 0001834105 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$35.00K
Fiscal year ended 2026-06-30
Operating income
-$5.11M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

IMPACT BIOMEDICAL INC. (IBO) reported revenue of $35.00K and net income of $789.00K for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from IMPACT BIOMEDICAL INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

IMPACT BIOMEDICAL INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$35.00K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$5.11M
Net income$789.00K
Research & development$284.00K
Weighted-average diluted sharesUnavailable
Pretax income-$1.80M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$2.17M
General & administrativeUnavailable
Selling & marketing$5.00K

Balance

IMPACT BIOMEDICAL INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalentsUnavailable
Total assets$16.74M
Current assets$320.00K
Total liabilities$2.73M
Current liabilities$2.04M
Total equity incl. NCI$14.01M
Temporary (mezzanine) equityUnavailable
Inventory$62.00K
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$467.00K

Cash flow

IMPACT BIOMEDICAL INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$508.00K
Capital expendituresUnavailable
Investing cash flow$3.00K
Financing cash flowUnavailable
Net change in cash-$614.00K
Stock-based compensation$1.45M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$1.14M

Derived

IMPACT BIOMEDICAL INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-14597.1%
FCF marginUnavailable
SBC / revenue4140.0%
Current ratio0.16x
Revenue YoY growthUnavailable
Net margin2254.3%
R&D / revenue811.4%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IBO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-11View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.